Wave Life Sciences.
biotechnology company
- Reports this week
- 3
- Active events
- 2
- Connections
- 39
What's happening
Active this week
One to three months ago
Gone quiet
No new reports in 90+ days-
Wave Life Sciences is seeking the accelerated approval pathway from the FDA ahead of mid-2026 feedback.Some support2 reports
-
H.C. Wainwright reaffirmed a buy rating on Wave Life Sciences, which also presented preclinical evidence at an ADA meeting in Chicago.Speculative1 report
-
Both CRISPR Therapeutics and Wave Life Sciences operate within the medical/biomedical industry.Some support1 report
-
Wave Life Sciences presented preclinical data at ADA Scientific Sessions on July 15, 2025.Some support3 reports
-
Wave Life Sciences delivered positive data from the N531 trial, with future milestones and payments remaining uncertain.Some support2 reports
-
Wave Life Sciences, based in Singapore, is developing therapies for DMD and targeting Huntington’s disease.Some support1 report
-
Wells Fargo lowered its price target on September 5, 2025, following trial results related to Wave Life Sciences.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Wave Life Sciences this week
News at the entities that move Wave Life Sciences most-
Delaware StructuralA nor'easter is impacting the coastlines of Delaware and Jersey Shore, causing coastal flooding and high waves.Moves Wave Life Sciences
-
Nasdaq StructuralApple Inc. stock is traded on Nasdaq, and Jefferies Financial Group restated a hold rating on the company.Moves Wave Life Sciences
-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Wave Life Sciences
-
Truist Financial Mentioned togetherMarketBeat aggregates data on Inventiva's stock, and Truist Financial has started coverage of the company.Moves Wave Life Sciences
-
Chicago Shared contextThe Chicago City Council requires council approval for appointments.Moves Wave Life Sciences
-
Cambridge Shared contextA book featuring Alice Hoffman is set in Cambridge during the 1950s.Moves Wave Life Sciences
Connections
The 12 strongest of 39, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Delaware Structural
Wave Life Sciences has redomiciled its corporate operations to operate under the laws of the State of Delaware.
-
Nasdaq Structural
Wave Life Sciences is formally listed and trades on the Nasdaq stock exchange.
-
FDA Structural
Wave Life Sciences is seeking accelerated approval pathway from the FDA.
-
Christopher Wright Structural
Christopher Wright holds the position of Chief Medical Officer at Wave Life Sciences.
-
Mizuho Transactional
Mizuho issued a price objective assessment regarding Wave Life Sciences.
-
Regeneron Pharmaceuticals Mentioned together
The two healthcare companies are mentioned in the same context as peers being compared.
-
Chicago Shared context
Wave Life Sciences presented preclinical data and sessions at events held in Chicago.
-
mash Mentioned together
Wave Life Sciences is involved in clinical trials that evaluate indications, including MASH.
Show all 12 connections
-
Truist Financial Mentioned together
Truist Financial has initiated financial coverage and monitoring of Wave Life Sciences.
-
Singapore Shared context
Wave Life Sciences was previously based in Singapore but is currently seeking redomiciliation from the jurisdiction.
-
Eli Lilly and Company Mentioned together
Both companies are mentioned as part of the drugmaker industry observing IPO market activity.
-
Cambridge Shared context
Wave Life Sciences is headquartered in Cambridge, MA.
History
Events by the month they beganSeptember 2026
2 eventsAugust 2026
1 eventJune 2026
8 events- Wave Life Sciences established its company headquarters in Cambridge, Massachusetts.
- Wave Life Sciences is seeking the accelerated approval pathway from the FDA ahead of mid-2026 feedback.
- H.C. Wainwright reaffirmed a buy rating on Wave Life Sciences, which also presented preclinical evidence at an ADA meeting in Chicago.
- Both CRISPR Therapeutics and Wave Life Sciences operate within the medical/biomedical industry.
- Wave Life Sciences presented preclinical data at ADA Scientific Sessions on July 15, 2025.
- Wave Life Sciences delivered positive data from the N531 trial, with future milestones and payments remaining uncertain.
- Wave Life Sciences, based in Singapore, is developing therapies for DMD and targeting Huntington’s disease.
- Wells Fargo lowered its price target on September 5, 2025, following trial results related to Wave Life Sciences.